Mylan Inc. : MYL

All MYL Articles

180 Articles

Trey Thoelcke | Dec 10, 2015 at 6:10 AM EST

The 6 Most Shorted Nasdaq Stocks: Short Sellers Pile on Apple

Short sellers piled on to Apple again between the November 13 and November 30 settlement dates, lifting its short interest…

Chris Lange | Nov 16, 2015 at 1:05 PM EST

What Perrigo and Teva Can Learn From Mylan’s Share Repurchase

Mylan announced Monday that it would be conducting a share repurchase for up to $1 billion, in a much faster…

Trey Thoelcke | Nov 11, 2015 at 7:03 AM EST

The 6 Most Shorted Nasdaq Stocks: Short Sellers Shy Away From Apple

Between the October 15 and October 30 settlement dates, short interest declined in many of the most heavily shorted stocks…

Chris Lange | Oct 30, 2015 at 8:45 AM EDT

Is Mylan’s Topline Growth Enough for Investors?

Mylan reported better-than-expected third-quarter financial results before the markets opened on Friday.

Chris Lange | Oct 29, 2015 at 1:05 PM EDT

What to Expect From Mylan Earnings

Mylan is scheduled to release its third-quarter financial results before the markets open on Friday.

Trey Thoelcke | Oct 9, 2015 at 7:05 AM EDT

Generics Giants Like Teva and Mylan May Now Join the Buy-and-Raise Craze

Martin Shkreli has said he would lower the price of Daraprim back down but hasn’t actually done it. He probably…

Chris Lange | Aug 25, 2015 at 1:55 PM EDT

Mylan Fires Back at Perrigo

Mylan announced Tuesday, in conjunction with the Irish Takeover Panel, that Perrigo had made misleading statements to shareholders.

Lee Jackson | Aug 20, 2015 at 8:20 AM EDT

Big Catalysts Coming Within a Week for 2 Specialty Pharmaceutical Stocks

ThinkstockWith biotech and specialty pharmaceutical stocks, catalysts and binary events can drive the stocks much higher, or in some cases…

Jon C. Ogg | Aug 12, 2015 at 7:35 AM EDT

5 Top BioPharma Stocks That May Have Sold Off Too Much and Become Bargains

It may be impossible to ever know if a true bottom has ever been seen, but many investors love finding…

Lee Jackson | Aug 11, 2015 at 10:35 AM EDT

UBS Makes Big Changes to Quality Growth at a Reasonable Price Portfolio

A new research report from UBS makes an interesting switch in the Quality Growth At a Reasonable Price (Q-GARP) portfolio.

Chris Lange | Aug 7, 2015 at 2:34 PM EDT

Key Analyst Sees Mylan as a Value Play

ThinkstockMylan N.V. (NASDAQ: MYL) is considered a serious value play in the health care sector by a key analyst. Argus…

Jon C. Ogg | Aug 7, 2015 at 8:50 AM EDT

Top Analyst Upgrades and Downgrades: BankUnited, Barrick Gold, ConocoPhillips, Michael Kors, Mylan, Viacom, Disney and Many More

Friday's top analyst upgrades, downgrades and initiations include BankUnited, Barrick Gold, ConocoPhillips, Michael Kors, Mylan, Viacom and Disney.

Chris Lange | Aug 2, 2015 at 9:15 AM EDT

The 7 Most Important Earnings in the Week Ahead

Frank Golhen, via Wikimedia Commons24/7 Wall St. has put together a preview of some of the major companies reporting their…

Jon C. Ogg | Jul 31, 2015 at 1:44 PM EDT

Teva Proves Its Decade-Hold Status With Massive Funding

ThinkstockTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) may have just proved how financially fit and capable the company is. On Friday…

Trey Thoelcke | Jul 15, 2015 at 7:20 AM EDT

Why Teva Pharmaceutical Bid for Mylan May Go Hostile

Teva could be about to enter the largest generic market by prescription in the world, which may tip the scales…

1 … 5 6 7 8 9 … 12

Mylan Inc. : MYL

All MYL Articles

The 6 Most Shorted Nasdaq Stocks: Short Sellers Pile on Apple

What Perrigo and Teva Can Learn From Mylan’s Share Repurchase

The 6 Most Shorted Nasdaq Stocks: Short Sellers Shy Away From Apple

Is Mylan’s Topline Growth Enough for Investors?

What to Expect From Mylan Earnings

Generics Giants Like Teva and Mylan May Now Join the Buy-and-Raise Craze

Mylan Fires Back at Perrigo

Big Catalysts Coming Within a Week for 2 Specialty Pharmaceutical Stocks

5 Top BioPharma Stocks That May Have Sold Off Too Much and Become Bargains

UBS Makes Big Changes to Quality Growth at a Reasonable Price Portfolio

Key Analyst Sees Mylan as a Value Play

Top Analyst Upgrades and Downgrades: BankUnited, Barrick Gold, ConocoPhillips, Michael Kors, Mylan, Viacom, Disney and Many More

The 7 Most Important Earnings in the Week Ahead

Teva Proves Its Decade-Hold Status With Massive Funding

Why Teva Pharmaceutical Bid for Mylan May Go Hostile

‘Traders Need to Be Really Careful Here’: Schwab on the Fed Decision and Powell’s Uncertain Future

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

This Dividend ETF Is up 30% in 6 Months With a 3.7% Dividend Yield

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Long-Term Care Could Cost This 68-Year-Old Couple $380,000 and Their $2.1 Million Portfolio Is Not Structured for It

‘Traders Need to Be Really Careful Here’: Schwab on the Fed Decision and Powell’s Uncertain Future

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Mylan Inc. : MYL

All MYL Articles

The 6 Most Shorted Nasdaq Stocks: Short Sellers Pile on Apple

What Perrigo and Teva Can Learn From Mylan’s Share Repurchase

The 6 Most Shorted Nasdaq Stocks: Short Sellers Shy Away From Apple

Is Mylan’s Topline Growth Enough for Investors?

What to Expect From Mylan Earnings

Generics Giants Like Teva and Mylan May Now Join the Buy-and-Raise Craze

Mylan Fires Back at Perrigo

Big Catalysts Coming Within a Week for 2 Specialty Pharmaceutical Stocks

5 Top BioPharma Stocks That May Have Sold Off Too Much and Become Bargains

UBS Makes Big Changes to Quality Growth at a Reasonable Price Portfolio

Key Analyst Sees Mylan as a Value Play

Top Analyst Upgrades and Downgrades: BankUnited, Barrick Gold, ConocoPhillips, Michael Kors, Mylan, Viacom, Disney and Many More

The 7 Most Important Earnings in the Week Ahead

Teva Proves Its Decade-Hold Status With Massive Funding

Why Teva Pharmaceutical Bid for Mylan May Go Hostile

‘Traders Need to Be Really Careful Here’: Schwab on the Fed Decision and Powell’s Uncertain Future

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

This Dividend ETF Is up 30% in 6 Months With a 3.7% Dividend Yield

Featured Reads

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Long-Term Care Could Cost This 68-Year-Old Couple $380,000 and Their $2.1 Million Portfolio Is Not Structured for It